B2M
Beta-2-microglobulin
Also known as: B2MG_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P61769
- Gene
- B2M
- Ensembl
- ENSG00000166710
- Chromosome
- 15
- Canonical length
- 119 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters
- Subcellular location
- Golgi apparatus,Plasma membrane,Cytosol
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a serum protein found in association with the major histocompatibility complex (MHC) class I heavy chain on the surface of nearly all nucleated cells. The protein has a predominantly beta-pleated sheet structure that can form amyloid fibrils in some pathological conditions. The encoded antimicrobial protein displays antibacterial activity in amniotic fluid. A mutation in this gene has been shown to result in hypercatabolic hypoproteinemia.[provided by RefSeq, Aug 2014]
Canonical amino-acid sequenceUniProt
119 residues, UniProt reviewed canonical sequence.
>P61769|B2M
1 MSRSVALAVL ALLSLSGLEA IQRTPKIQVY SRHPAENGKS NFLNCYVSGF HPSDIEVDLL
61 KNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against B2M can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 8,709 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 8,709 nTPM
- spleen: 7,433 nTPM
- bone marrow: 7,390 nTPM
- lung: 5,807 nTPM
- liver: 5,792 nTPM
- urinary bladder: 5,381 nTPM
Single-cell type
- enterocytes: 5,903 nCPM
- kupffer cells: 5,841 nCPM
- platelets: 5,107 nCPM
- decidual stromal cells: 4,907 nCPM
- plasma cells: 3,862 nCPM
- cdc: 3,645 nCPM
Immune cell
- total PBMC: 55,984 nTPM
- neutrophil: 49,775 nTPM
- basophil: 47,420 nTPM
- eosinophil: 32,671 nTPM
- T-reg: 29,216 nTPM
- memory CD4 T-cell: 23,466 nTPM
Brain region
- white matter: 817 nTPM
- medulla oblongata: 769 nTPM
- spinal cord: 663 nTPM
- choroid plexus: 556 nTPM
- thalamus: 541 nTPM
- hypothalamus: 523 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about B2M.
Disease | AllUniProt
Conditions B2M is implicated in, by any mechanism.
- Immunodeficiency 43 (IMD43) MIM:241600
- Amyloidosis, hereditary systemic 6 (AMYLD6) MIM:620659
Disease | GeneticClinVar
5 pathogenic / likely-pathogenic of 101 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hypoproteinemia, hypercatabolic
- Familial visceral amyloidosis, Ostertag type
- Non-Hodgkin lymphoma
- Amyloidosis, hereditary systemic 6
Disease | AutoantibodyPubMed
Conditions in which antibodies against B2M are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for B2M from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
18 publications
- Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes.
1993 · J Cell Biol · RCR 3.6 · 102 citations - Use of the ELISA to screen for anti-thymocyte and anti-beta 2-microglobulin antibodies in leprosy and SLE.
1980 · Immunology · RCR 2 · 41 citations - Antibodies to beta 2 microglobulin in the sera of patients with systemic lupus erythematosus.
1977 · Immunology · RCR 1.6 · 57 citations - Demonstration of electrophoretic heterogeneity of serum beta 2-microglobulin in systemic lupus erythematosus and rheumatoid arthritis: evidence against autoantibodies to beta 2-microglobulin.
1979 · Scand J Immunol · RCR 1.4 · 46 citations - Rheumatoid factors from patients with rheumatoid arthritis react with beta 2-microglobulin.
1992 · J Immunol · RCR 0.9 · 29 citations
Show 13 more
- Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients.
1982 · Arthritis Rheum · RCR 0.9 · 32 citations - T lymphocyte interaction with immunoglobulin G antibody in systemic lupus erythematosus.
1982 · J Clin Invest · RCR 0.9 · 31 citations - Beta-2-microglobulin-specific autoantibodies cause platelet aggregation and interfere with ADP-induced aggregation.
1982 · Clin Exp Immunol · RCR 0.5 · 16 citations - Auto-antibodies specific for beta 2 microglobulin in normal human serum.
1983 · Mol Immunol · RCR 0.5 · 20 citations - Prevalence of anti-beta-2 microglobulin autoantibodies in sera of rheumatoid arthritis patients with extra-articular manifestations.
1981 · Ann Rheum Dis · RCR 0.5 · 10 citations - Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients.
1993 · J Acquir Immune Defic Syndr (1988) · RCR 0.4 · 16 citations - Characterization of polyclonal autoantibodies specific for beta 2-microglobulin in multiple myeloma sera.
1983 · Clin Exp Immunol · RCR 0.2 · 5 citations - Relationship of anti-beta 2-microglobulin antibodies to T11 and T-cell activation in systemic lupus erythematosus.
1985 · Clin Immunol Immunopathol · RCR 0.1 · 5 citations - Titer and specificity of autoantibody to beta 2-microglobulin in sera from patients with rheumatic disease.
1990 · Microbiol Immunol · RCR 0.1 · 2 citations - Calreticulin associates with non-HLA-A,-B class I proteins in the human choriocarcinoma cell lines JEG-3 and BeWo.
1998 · Immunology · RCR 0.1 · 4 citations - Induction of human rheumatoid factor and other autoantibodies by bacterial lipopolysaccharide.
1985 · Acta Microbiol Hung · RCR 0 · 1 citations - Interference of beta 2-microglobulin specific autoantibodies with EA-binding of human peripheral lymphocytes; inhibition of B-cell and enhancement of T-lymphocyte Fc-receptors.
1981 · Immunol Lett - [Anti-beta-2-microglobulin antibodies in systemic lupus erythematosus].
1997 · Rev Hosp Clin Fac Med Sao Paulo
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.71
- gnomAD pLI
- 0.56
- gnomAD missense Z
- 0.81
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- amyloid fibril formation
- antigen processing and presentation of endogenous peptide antigen via MHC class I
- antigen processing and presentation of exogenous peptide antigen via MHC class II
- antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent
- cellular response to iron ion
- cellular response to iron(III) ion
- cellular response to nicotine
- intracellular iron ion homeostasis
- learning or memory
- multicellular organismal-level iron ion homeostasis
- negative regulation of epithelial cell proliferation
- negative regulation of forebrain neuron differentiation
- negative regulation of neurogenesis
- negative regulation of neuron projection development
- negative regulation of receptor-mediated endocytosis
- peptide antigen assembly with MHC class I protein complex
- peptide antigen assembly with MHC class II protein complex
- positive regulation of cellular senescence
- positive regulation of immune response
- positive regulation of receptor-mediated endocytosis
- positive regulation of T cell activation
- positive regulation of T cell cytokine production
- positive regulation of T cell mediated cytotoxicity
- protein homotetramerization
- protein refolding
- regulation of erythrocyte differentiation
- regulation of iron ion transport
- response to molecule of bacterial origin
- sensory perception of smell
- T cell differentiation in thymus
- T cell mediated cytotoxicity
- transferrin transport
- negative regulation of iron ion transport
Molecular functions
- identical protein binding
- MHC class II protein complex binding
- peptide antigen binding
- protein homodimerization activity
- structural molecule activity
Cellular components
- cytosol
- early endosome lumen
- early endosome membrane
- endoplasmic reticulum
- endoplasmic reticulum lumen
- ER to Golgi transport vesicle membrane
- external side of plasma membrane
- extracellular exosome
- extracellular region
- extracellular space
- focal adhesion
- Golgi apparatus
- Golgi membrane
- HFE-transferrin receptor complex
- late endosome membrane
- lysosomal membrane
- membrane
- MHC class I peptide loading complex
- MHC class I protein complex
- MHC class II protein complex
- phagocytic vesicle membrane
- plasma membrane
- recycling endosome membrane
- specific granule lumen
- tertiary granule lumen
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of B2M in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads B2M as an antibody target. Whether an autoantibody or antibody against B2M could matter depends on whether native B2M is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
B2M is annotated at the cell surface, where native B2M is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label B2M as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...